Despite lower-than-expected demand for a competing treatment, DBV’s chief medical officer says...
Author - simom
As the opioid crisis seethes, a long-lasting treatment could...
Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.
What happened to ivermectin?
The saga of the anti-parasitic drug continues.
PBMs, PhRMA trade blame over drug costs in House hearing
Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the...
DCTs create fresh privacy challenges for review boards. Now...
A new toolkit developed by industry stakeholders paves the way for faster reviews.
Flagship, PhRMA prioritize experience in hot summer exec changes
With major projects brewing at both organizations, these new leaders will hit the ground running.
Novo’s workhorse Ozempic could shine in new areas
Besides its popularity as a weight loss drug, Ozempic and treatments like it are being investigated...
FDA’s upcoming psychedelic review looms large for a budding...
A new psychedelic guidance from the agency gives a clue into how it could analyze drugs in the...
A rare disease veteran, Inozyme’s new CEO sharpens the...
After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through...
Merck’s New Jersey campus is getting a biotech makeover
With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the...